The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Psoriasis Drugs-Global Market Insights and Sales Trends 2025

Psoriasis Drugs-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1839676

No of Pages : 86

Synopsis
The global Psoriasis Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Psoriasis Drugs in various end use industries. The expanding demands from the Topicals, Systemic and Biologics,, are propelling Psoriasis Drugs market. Tumor Necrosis Factor Inhibitor, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Interleukin Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Psoriasis Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Psoriasis Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Psoriasis Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Psoriasis Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Psoriasis Drugs covered in this report include AbbVie, Amgen, Johnson & Johnson, Novartis, Eli Lilly & Company, AstraZeneca, Celgene Corporation, UCB and Merck, etc.
The global Psoriasis Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AbbVie
Amgen
Johnson & Johnson
Novartis
Eli Lilly & Company
AstraZeneca
Celgene Corporation
UCB
Merck
Global Psoriasis Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Psoriasis Drugs market, Segment by Type:
Tumor Necrosis Factor Inhibitor
Interleukin Inhibitors
Others
Global Psoriasis Drugs market, by Application
Topicals
Systemic
Biologics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Psoriasis Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index
1 Market Overview of Psoriasis Drugs
1.1 Psoriasis Drugs Market Overview
1.1.1 Psoriasis Drugs Product Scope
1.1.2 Psoriasis Drugs Market Status and Outlook
1.2 Global Psoriasis Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Psoriasis Drugs Market Size by Region (2018-2029)
1.4 Global Psoriasis Drugs Historic Market Size by Region (2018-2023)
1.5 Global Psoriasis Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Psoriasis Drugs Market Size (2018-2029)
1.6.1 North America Psoriasis Drugs Market Size (2018-2029)
1.6.2 Europe Psoriasis Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Psoriasis Drugs Market Size (2018-2029)
1.6.4 Latin America Psoriasis Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Psoriasis Drugs Market Size (2018-2029)
2 Psoriasis Drugs Market by Type
2.1 Introduction
2.1.1 Tumor Necrosis Factor Inhibitor
2.1.2 Interleukin Inhibitors
2.1.3 Others
2.2 Global Psoriasis Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Psoriasis Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Psoriasis Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Psoriasis Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Psoriasis Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Psoriasis Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Psoriasis Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Psoriasis Drugs Revenue Breakdown by Type (2018-2029)
3 Psoriasis Drugs Market Overview by Application
3.1 Introduction
3.1.1 Topicals
3.1.2 Systemic
3.1.3 Biologics
3.2 Global Psoriasis Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Psoriasis Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Psoriasis Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Psoriasis Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Psoriasis Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Psoriasis Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Psoriasis Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Psoriasis Drugs Revenue Breakdown by Application (2018-2029)
4 Psoriasis Drugs Competition Analysis by Players
4.1 Global Psoriasis Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Psoriasis Drugs as of 2022)
4.3 Date of Key Players Enter into Psoriasis Drugs Market
4.4 Global Top Players Psoriasis Drugs Headquarters and Area Served
4.5 Key Players Psoriasis Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Psoriasis Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AbbVie
5.1.1 AbbVie Profile
5.1.2 AbbVie Main Business
5.1.3 AbbVie Psoriasis Drugs Products, Services and Solutions
5.1.4 AbbVie Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 AbbVie Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Psoriasis Drugs Products, Services and Solutions
5.2.4 Amgen Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 Johnson & Johnson
5.3.1 Johnson & Johnson Profile
5.3.2 Johnson & Johnson Main Business
5.3.3 Johnson & Johnson Psoriasis Drugs Products, Services and Solutions
5.3.4 Johnson & Johnson Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Psoriasis Drugs Products, Services and Solutions
5.4.4 Novartis Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis Recent Developments
5.5 Eli Lilly & Company
5.5.1 Eli Lilly & Company Profile
5.5.2 Eli Lilly & Company Main Business
5.5.3 Eli Lilly & Company Psoriasis Drugs Products, Services and Solutions
5.5.4 Eli Lilly & Company Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Eli Lilly & Company Recent Developments
5.6 AstraZeneca
5.6.1 AstraZeneca Profile
5.6.2 AstraZeneca Main Business
5.6.3 AstraZeneca Psoriasis Drugs Products, Services and Solutions
5.6.4 AstraZeneca Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 AstraZeneca Recent Developments
5.7 Celgene Corporation
5.7.1 Celgene Corporation Profile
5.7.2 Celgene Corporation Main Business
5.7.3 Celgene Corporation Psoriasis Drugs Products, Services and Solutions
5.7.4 Celgene Corporation Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Celgene Corporation Recent Developments
5.8 UCB
5.8.1 UCB Profile
5.8.2 UCB Main Business
5.8.3 UCB Psoriasis Drugs Products, Services and Solutions
5.8.4 UCB Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 UCB Recent Developments
5.9 Merck
5.9.1 Merck Profile
5.9.2 Merck Main Business
5.9.3 Merck Psoriasis Drugs Products, Services and Solutions
5.9.4 Merck Psoriasis Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Merck Recent Developments
6 North America
6.1 North America Psoriasis Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Psoriasis Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Psoriasis Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Psoriasis Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Psoriasis Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Psoriasis Drugs Market Dynamics
11.1 Psoriasis Drugs Industry Trends
11.2 Psoriasis Drugs Market Drivers
11.3 Psoriasis Drugs Market Challenges
11.4 Psoriasis Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’